Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC – The ASCO Post

By The ASCO Post StaffPosted: 12/19/2019 10:18:00 AM Last Updated: 12/20/2019 1:45:32 PM Few grade 3 or higher immune-related adverse events were observed in patients treated with first-line durvalumab plus platinum/etoposide for extensive-stage small cell lung cancer (SCLC), according to…

Read the full article here

Related Articles